VSV-ZEBOV is an investigational Ebola vaccine currently being tested for safety and the ability to generate an immune response in healthy adults.
VSV-ZEBOV was developed by researchers at the Public Health Agency of Canada’s National Microbiology Laboratory. It has been licensed to NewLink Genetics Corp through its wholly owned subsidiary BioProtection Systems, both based in Ames, Iowa.
The vaccine is being tested as two intramuscular doses by the National Institute of Allergy and Infectious Diseases (NIAID), and as a single dose at the Walter Reed Army Institute of Research (WRAIR). The NIH Phase 1 clinical trial of the VSV-ZEBOV vaccine candidate will enroll 39 healthy adults aged 18 to 65 years.
Initial safety and immune response data on the VSV-ZEBOV vaccine are expected by the end of 2014.